Jason S Knight1, Mariana J Kaplan. 1. Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-5680, USA.
Abstract
PURPOSE OF REVIEW: With improved management of the classical disease manifestations of systemic lupus erythematosus (SLE), cardiovascular disease (CVD) has emerged as one of the most important causes of morbidity and mortality. This review in particular focuses on progress over the past year in clinical and basic aspects of SLE-driven accelerated atherosclerosis. RECENT FINDINGS: Both subclinical CVD and CV events continue to be recognized at increased frequency in previously unstudied lupus cohorts and populations. Novel associations have been identified between lupus CVD and cognitive impairment, depression, and low-income status. In terms of pathogenesis, there is an ever-increasing focus on the innate immune system and, in particular, type I interferons (IFNs). Recent studies have drawn connections in both human and murine models between neutrophils, plasmacytoid dendritic cells, type I IFNs, and endothelial dysfunction. Whether treatments such as mycophenolate mofetil or statins have a role in prevention of lupus CVD is an area of intensive study. SUMMARY: CVD is a major complication of lupus and is now a leading cause of death among people living with this disease. As such, additional studies are needed in order to identify the most effective preventive strategies and most predictive vascular risk biomarkers. Type I IFNs may play a critical role in lupus CVD pathogenesis, and it is recommended that vascular outcomes be included in ongoing trials testing the efficacy of anti-IFN biologics.
PURPOSE OF REVIEW: With improved management of the classical disease manifestations of systemic lupus erythematosus (SLE), cardiovascular disease (CVD) has emerged as one of the most important causes of morbidity and mortality. This review in particular focuses on progress over the past year in clinical and basic aspects of SLE-driven accelerated atherosclerosis. RECENT FINDINGS: Both subclinical CVD and CV events continue to be recognized at increased frequency in previously unstudied lupus cohorts and populations. Novel associations have been identified between lupus CVD and cognitive impairment, depression, and low-income status. In terms of pathogenesis, there is an ever-increasing focus on the innate immune system and, in particular, type I interferons (IFNs). Recent studies have drawn connections in both human and murine models between neutrophils, plasmacytoid dendritic cells, type I IFNs, and endothelial dysfunction. Whether treatments such as mycophenolate mofetil or statins have a role in prevention of lupus CVD is an area of intensive study. SUMMARY: CVD is a major complication of lupus and is now a leading cause of death among people living with this disease. As such, additional studies are needed in order to identify the most effective preventive strategies and most predictive vascular risk biomarkers. Type I IFNs may play a critical role in lupus CVD pathogenesis, and it is recommended that vascular outcomes be included in ongoing trials testing the efficacy of anti-IFN biologics.
Authors: Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major Journal: Proc Natl Acad Sci U S A Date: 2006-04-24 Impact factor: 11.205
Authors: L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson Journal: Arthritis Rheum Date: 2012-01
Authors: Axelle Caudrillier; Kai Kessenbrock; Brian M Gilliss; John X Nguyen; Marisa B Marques; Marc Monestier; Pearl Toy; Zena Werb; Mark R Looney Journal: J Clin Invest Date: 2012-06-11 Impact factor: 14.808
Authors: Patrick Ahearn; Kirsten L Johansen; Charles E McCulloch; Barbara A Grimes; Elaine Ku Journal: Am J Kidney Dis Date: 2018-10-11 Impact factor: 8.860
Authors: Jason S Knight; Wei Luo; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Venkataraman Subramanian; Chiao Guo; Robert C Grenn; Paul R Thompson; Daniel T Eitzman; Mariana J Kaplan Journal: Circ Res Date: 2014-01-14 Impact factor: 17.367